Recent Developments in Neisseria Meningitidis Group A Conjugate Vaccines
This article, published in Expert Opinion on Biological Therapy, focuses on the development of meningococcal conjugate vaccines for serogroup A, with special emphasis on the needs of Africa. The author discusses the currently available conjugate vaccine against serogroup C, and the benefits of developing a conjugate vaccine against serotype A for developing-country populations, particularly children. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Frasch CE
Visit web page (English)
(Located at www.ncbi.nlm.nih.gov)
Citation: Frasch CE. Recent Developments in Neisseria Meningitidis Group A Conjugate Vaccines. Expert Opinion on Biological Therapy. 2005;5(2):273-280.